Chronic lymphocytic leukemia
GPTKB entity
Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Rituximab
gptkb:Pharmacyclics |
| gptkbp:affects |
blood cells
|
| gptkbp:clinical_trial |
ongoing studies
new drug approvals combination therapies |
| gptkbp:complications |
gptkb:fandom
infections thrombocytopenia |
| gptkbp:current_use |
autoimmune disorders
hypogammaglobulinemia Richter's transformation |
| gptkbp:end_of_life |
varies by treatment
improving over time |
| gptkbp:first_described_by |
in 1856
|
| gptkbp:genetic_diversity |
recommended for some patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chronic lymphocytic leukemia
|
| gptkbp:is_monitored_by |
clinical evaluations
regular blood tests symptom tracking |
| gptkbp:is_popular_in |
more common in men
more common in older adults |
| gptkbp:live_performance |
Binet staging system
Rai staging system |
| gptkbp:research_focus |
biomarkers
genetic mutations new therapies |
| gptkbp:risk_factor |
age
family history exposure to certain chemicals |
| gptkbp:scholarships |
gptkb:Educational_Institution
counseling services support groups |
| gptkbp:social_responsibility |
blood test
varies by stage bone marrow biopsy depends on genetic factors |
| gptkbp:symptoms |
fatigue
weight loss night sweats swollen lymph nodes |
| gptkbp:treatment |
gptkb:venetoclax
gptkb:ibrutinib gptkb:vaccine gptkb:chlorambucil chemotherapy targeted therapy fludarabine |